O'Shaughnessy J. Treatment options for patients with HR+/HER2- advanced breast cancer during the COVID-19 pandemic: dose reduction of ribociclib does not diminish efficacy. Breast Cancer Res Treat 2020 May 20. pii: 10.1007/s10549-020-05674.
PMID: 32436148